Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: Successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation

Leukemia

Volumn 22, Issue 10, 2008, Pages 1961-1963

  Benjamini, O ^a   Koren Michowitz, M ^a   Amariglio, N ^a   Kroger, N ^a   Nagler, A ^a   Shimoni, A ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; FLUDARABINE; HYDROXYUREA; JANUS KINASE 2; STEROID; THALIDOMIDE; THYMOCYTE ANTIBODY;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CD34 SELECTION; DONOR LYMPHOCYTE INFUSION; GENE MUTATION; GRAFT VERSUS HOST REACTION; HEMATOCRIT; HUMAN; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; MYELOID METAPLASIA; PHLEBOTOMY; POLYCYTHEMIA MYELOID METAPLASIA; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; SPLENECTOMY; SPLENOMEGALY; THROMBOCYTE COUNT;

EID: 54049126083     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.215     Document Type: Article

References (8)

1. Papageorgiou SG, Castelton A, Bloor A, Kottaridis PD. Allogeneic stem cell transplantation as treatment for myelofibrosis. Bone Marrow Transplant 2006; 38: 721-727.
2. Kröger N, Thiele J, Zander A, Schwerdtfeger R, Kobbe G, Bornhäuser M et al. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. Exp Hematol 2007; 35: 1719-1722.
3. Cervantes F, Rovira M, Urbano-Ispizua A, Rozman M, Carreras E, Montserrat E. Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect. Bone Marrow Transplant 2000; 26: 697-699.
4. Koren-Michowitz M, Shimoni A, Vivante A, Trakhtenbrot L, Rechavi G, Amariglio N et al. A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD). Leuk Res 2008; 32: 421-427.
5. Talarico L, Wolf BC, Kumar A, Weintraub LR. Reversal of bone marrow fibrosis and subsequent development of polycythemia in patients with myeloproliferative disorders. Am J Hematol 1989; 30: 248-253.
6. Shimoni A, Nagler A. Non-myeloablative stem cell transplantation (NST): chimerism testing as guidance for immune-therapeutic manipulations. Leukemia 2001; 15: 1967-1975.
7. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L et al. Cross Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162-2168.
8. Kröger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornhäuser M et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007; 109: 1316-1321.